Betaferon Use in Children and Adolescents With Multiple Sclerosis

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT03577977

2008/01743

Details and patient eligibility

About

The objective of this study is to determine efficacy, safety and tolerability of interferon beta-1b for multiple sclerosis (MS) in children and adolescents

Enrollment: 70 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with symptoms consistent with the diagnosis of a demyelinating CNS disease
• patients who received at least one injection of Betaferon before age 18 (before their 18th birthday)
• recorded use of at least one dose of Betaferon before January 1, 2008

Exclusion criteria

• Diagnosis other then MS or a demyelinating CNS disease

Trial design

70 participants in 1 patient group

Patients treated with Betaferon

Description:

Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.

Treatment:

Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)